<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411381</url>
  </required_header>
  <id_info>
    <org_study_id>TELE_RVS</org_study_id>
    <nct_id>NCT04411381</nct_id>
  </id_info>
  <brief_title>Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients</brief_title>
  <official_title>Telemedicine-based Model of Care for the Management of Hepatitis C Infected Patients: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of La Laguna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of La Laguna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To achieve World Health Organization 2030 goals of hepatitis C elimination it is mandatory to&#xD;
      document after treatment sustained virological response (SVR). Currently, patients after&#xD;
      completing treatment do not show up for SVR assessment. The main objective of this study is&#xD;
      to evaluate the effectiveness of a telemedicine-based model of care associated with dried&#xD;
      blood spot testing at home to assess hepatitis C sustained virological response after&#xD;
      treatment compared to the traditional model of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized study in which hepatitis C (VHC) infected patients will be&#xD;
      randomized to two strategies for HCV care.&#xD;
&#xD;
      All HCV infected patients will be evaluated in a first face-to-face consultation with the&#xD;
      hepatologist for fibrosis evaluation and treatment prescription the same day. Patients will&#xD;
      be invited to participate if they are: 1) 18 years or older 2) have contact telephone number&#xD;
      3) sing the informed consent 4) have not advanced fibrosis (F3) or cirrhosis (F4) 5) are not&#xD;
      under surveillance by another specialist or drug addiction centre.&#xD;
&#xD;
      Participants will be randomized into two strategies to assess sustained virological response&#xD;
      (SVR) during follow-up:&#xD;
&#xD;
        1. The traditional model of care: one appointment for venipuncture for RNA testing to&#xD;
           assess SVR (undetectable RNA 12 weeks after treatment cessation), and an appointment&#xD;
           with the specialist for result communication.&#xD;
&#xD;
        2. Telemedicine-based model of care: The patient will be provided with a home kit to&#xD;
           perform the dried blood spot (DBS) testing for HCV RNA at 12 weeks (SVR), and an&#xD;
           appointment for teleconsultation and communicate the results.&#xD;
&#xD;
      Demographic, clinical and laboratory data will be collected to evaluate the characteristics&#xD;
      of included patients and to study predictive factors of adherence.&#xD;
&#xD;
      A satisfaction questionnaire will be conducted to compare patients´ satisfaction with both&#xD;
      health care models.&#xD;
&#xD;
      The hypothesis of the study is that the adherence and SVR determination record will increase&#xD;
      using the telemedicine-based model of care.&#xD;
&#xD;
      For the present study, a 20% improvement in the adherence (SVR record) was hypothesized in&#xD;
      the group of patients randomized to the telemedicine-based model of care compared to the&#xD;
      traditional model of care. Taking into account power of 80%, alpha error of 5% and losses of&#xD;
      10% will require 68 patients per group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of the two models of care</measure>
    <time_frame>12 months</time_frame>
    <description>SVR record rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptance of the intervention with a validated satisfaction questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Grade of patient satisfaction with telemedicine by a validated questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Telemedicine</condition>
  <arm_group>
    <arm_group_label>Telemedicine-based model of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional model of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Tradiotional model of care with venipuncture for RNA test to sustained virological response determination and face-to-face consultation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telemedicine</intervention_name>
    <description>Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination</description>
    <arm_group_label>Telemedicine-based model of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  have contact telephone number&#xD;
&#xD;
          -  sing the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have advanced fibrosis (F3) or cirrhosis (F4)&#xD;
&#xD;
          -  are under surveillance by another specialist or drug addition center.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Manuel Hernández-Guerra, PhD</last_name>
    <phone>34922678559</phone>
    <email>mhernand@ull.edu.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa CRUZ DE Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MANUEL HERNANDEZ GUERRA, PhD</last_name>
      <phone>922678000</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Gómez L, Reygosa C, Morales-Arráez DE, Ramos R, Pérez A, Hernández A, Quintero E, Gutiérrez F, Diaz-Flores F, Hernández-Guerra M. Diagnostic test accuracy of the cobas 6800 system for detection of hepatitis c virus viraemia levels from dried blood spots. Enferm Infecc Microbiol Clin (Engl Ed). 2020 Jun - Jul;38(6):267-274. doi: 10.1016/j.eimc.2019.10.009. Epub 2019 Dec 4. English, Spanish.</citation>
    <PMID>31812456</PMID>
  </reference>
  <reference>
    <citation>Averhoff F, Shadaker S, Gamkrelidze A, Kuchuloria T, Gvinjilia L, Getia V, Sergeenko D, Butsashvili M, Tsertsvadze T, Sharvadze L, Zarkua J, Skaggs B, Nasrullah M. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J Hepatol. 2020 Apr;72(4):680-687. doi: 10.1016/j.jhep.2019.11.019. Epub 2019 Dec 4.</citation>
    <PMID>31811882</PMID>
  </reference>
  <reference>
    <citation>Cuadrado A, Llerena S, Cobo C, Pallás JR, Mateo M, Cabezas J, Fortea JI, Alvarez S, Pellón R, Crespo J, Echevarría S, Ayesa R, Setién E, Lopez-Hoyos M, Crespo-Facorro B, Agüero J, Chueca N, Garcia F, Calleja JL, Crespo J. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. Am J Gastroenterol. 2018 Nov;113(11):1639-1648. doi: 10.1038/s41395-018-0157-x. Epub 2018 Jun 27.</citation>
    <PMID>29946175</PMID>
  </reference>
  <reference>
    <citation>Jiménez Galán G, Alia Alia C, Vegue González M, García Berriguete RMª, Fernández González F, Fernández Rodríguez CM, González Fernández M, Gutiérrez García ML, Losa JE, Velasco M, Moreno L, Hervás R, Delgado-Iribarren A, Palacios García-Cervigón G. The contribution of telemedicine to hepatitis C elimination in a correctional facility. Rev Esp Enferm Dig. 2019 Jul;111(7):550-555. doi: 10.17235/reed.2019.6152/2018.</citation>
    <PMID>31215210</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of La Laguna</investigator_affiliation>
    <investigator_full_name>Manuel Hernandez-Guerra, MD</investigator_full_name>
    <investigator_title>Head of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

